Dublin Steroid Cancer Meeting is a two-day unique meeting that aims to bring together world leaders in an intimate setting that will foster critical idea exchange, inspiration and collaboration. This year’s conference theme will focus on epigenetic and metabolic dysregulation in cancer, emerging immunotherapies and the influence of the tumour microenvironment, with talks on basic research and translational implications.
The conference chairs are currently developing their detailed programme, which will include the complete meeting schedule, as well as the talk titles for all invited speakers and short talks selected from abstract submissions. Please check back for updates.
Dublin Steroid Cancer Conference 2018
Chairs: Leonie Young, RCSI, Donald P McDonnell, Duke University, Damir Varešlija, RCSI
http://endoadapt.com/conference-programme/
Monday 15thOctober
08.00 –08:50 Registration,The Front Hall,RCSI, 123 St Stephen’s Green
08:50 – 9:00 Introductory Comments by the Conference Chair
Session 1: Genomic Approaches to Understanding Steroid Dependent Cancer
| 9:00-9:30 | Adrian Lee, University of Pittsburgh (USA)
The Genomics of Breast Cancer Metastasis |
| 9:30-10:00 | Leonie Young, Royal College of Surgeons in Ireland (Ireland)
Epigenetic and Transcriptomic Aberrations in Advanced Breast Cancer |
| 10:00-10:30 | Rachael Natrajan, The Institute of Cancer Research (UK)
Alternative Splicing as a Driver of ER+ Breast Cancer
|
Session Chairs: Ray Stallings, RCSI
Tea and coffee, The Front Hall, RCSI 10:30 – 11: 00
Session 2: Epigenetic Mechanisms of Cancer Progression
| 11:00-11:30 | Michael Kharas, Memorial Sloan Kettering Cancer Center (USA)
RNA regulators and epigenetic control of leukemia self-renewal |
| 11:30-12:00 | Adrian Bracken, Trinity College Dublin (Ireland)
A novel isoform of Ligand-dependent corepressor (LCOR) essential for Polycomb mediated repression and embryonic development |
| 12:00-12:30 | Giovanni Ciriello, University of Lausanne (Switzerland)
Cancer epigenetic dependencies in 3D |
| 12:30-13:00 | Jana Jeschke, Free University of Brussels (Belgium)
Detecting changes in the tumor microenvironment through epigenetic profiling |
Session Chairs: Darran O’Connor
Lunch and Poster viewing, The Exam Hall, RCSI 13.00 – 14.00
Session 3: Nuclear Receptor I
Session Chairs: Marie McIlroy
| 14:00-14:30 | Geoff Greene, University of Chicago (USA)
Novel Approaches to Exploiting Steroid Receptors in Breast Cancer |
| 14:30-15:00 | Myles Brown, Dana Farber Cancer Institute (USA)
Essential Cistromes Driving Hormone-Dependent Cancers |
| 15:00-15:30 | Wayne Tilley, University of Adelaide (Australia)
Targeting the androgen receptor in estrogen receptor-α positive breast cancer |
| 15:30-16:00 | Charlotte Bevan, Imperial College London (UK)
MicroRNAs, androgen receptor and therapy resistance in prostate cancer |
Tea and coffee, The Front Hall, RCSI 16:00 – 16: 30
Session 4 –SFI Keynote Speaker
Introduction: Donald P McDonnell
16:30 – 17:30 Bert O’Malley, Baylor College of Medicine (USA)
Can Coactivator Molecular Biology Substantiate Sugar as the ‘White Death’?
Tuesday 16th October
Session 5: Tumour Resistance Mechanisms
Session Chairs: Jochen Prehn and Arnold Hill
| 10:00-10:30 | Steffi Oesterreich, University of Pittsburgh (USA)
Mutant ER – Above and Beyond Endocrine Resistance |
| 10:30-11:00 | James Valerinano Alvarez, Duke University (USA)
Clonal dynamics during residual disease and recurrence |
| 11:00-11:15 | Suzan Stelloo, NKI, (Netherlands)
Integrative epigenetic taxonomy of primary prostate cancer |
| 11:15-11:30 | Claire Fletcher, Imperial College London (UK)
Mir-346 Interaction With Long Non-Coding Rna, Norad, Reveals A Novel Genome Protection Mechanism And Modulates Response To DNA-Damaging Therapeutics In Advanced Prostate Cancer |
Tea and coffee, The Front Hall, RCSI 11:30 – 12: 00
Session 6: Nuclear Receptors II
Session Chairs: Liam Gallagher
| 12:00-12:30 | Wilbert Zwart, NKI, Netherlands
From cistromics to novel therapeutics in hormone dependent cancers |
| 12:30-13:00 | Donald McDonnell, Duke University (USA)
Cancer cell selective inhibition of mitochondrial function as a therapeutic approach in breast cancer |
| 13:00-13.30 | Scott Dehm, University of Minnesota (USA)
Role and Origin of Androgen Receptor Variants in Prostate Cancer |
Lunch and Poster viewing, The Exam Hall, RCSI 13.30 – 14.30
Session 7: Model Systems and Novel Therapeutics
Session Chairs: Ann Hopkins
| 14:30-15:00 | Cathrin Brisken, Ecole Polytechnique Federale de Lausanne (Switzerland)
Humanizing mouse mammary glands to study hormone-dependent breast carcinogenesis |
| 15:00-15:30 | Karen Knudsen, Sidney Kimmel Cancer Center (USA)
Targeting AR-DNA Repair Crosstalk in Aggressive Prostate Cancer |
| 15:30-15:45 | Sara Charmsaz, RCSI (Ireland)
Therapeutic Targets and Companion Diagnostics in Endocrine Resistant Breast Cancer |
| 15:45-16:00 | Colm Ryan, UCD (Ireland)
The regulation of protein complexes in breast cancer |
| Tea and coffee, The Front Hall, RCSI 16:00 – 16: 30
|
|
| 16:30-17:00 | Triona Ni Chonghaile , RCSI (Ireland)
Discovery of a novel specific HDAC6 inhibitor |
| 17:00-17:30 | Tracy Robson, RCSI (Ireland)
Harnessing the Anti-angiogenic and Anti-cancer Stem Cell Properties of FKBPL; Discovery to Clinic |
Closing Remarks and General Discussion
